This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Sign In   |   Register
Reports and interviews

FHSC Investigators have had two abstracts accepted by the EAS Virtual Congress 2020:

• Abstract Title: ”Characteristics of Adults with Heterozygous Familial Hypercholesterolaemia stratified by gender: Preliminary analysis from the EAS FHSC Global Registry on over 36,000 cases of Familial Hypercholesterolaemia”. ACCEPTED as an Oral in a WORKSHOP session.

• Abstract Title: ”Heterozygous Familial Hypercholesterolaemia in Children: Preliminary analysis from the EAS FHSC Global Registry on over 7,900 children with Familial Hypercholesterolaemia”. ACCEPTED as an Oral in a SCIENCE AT A GLANCE session.

FHSC presents in Late-breaking session at ESC Congress 2019 Paris

Monday 2nd September 2019 – The first patient data from the European Atherosclerosis Society Familial Hypercholesterolaemia Studies Collaboration (FHSC), the only global registry on FH, highlight the need for more intensive therapy to reduce low-density lipoprotein cholesterol (LDL C), ‘bad cholesterol‘, in people with FH. Among 42,000 adults with heterozygous FH, only about half received a statin at the time of entry to the registry. Of people on a statin, over 85 per cent had LDL-C levels at entry that were above European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) recommended targets for people with FH. The findings were reported during the ESC Congress, 31 August-4 September, Paris, France.

Press release in full >>

First insights from the EAS FHSC Registry: FH is still underdiagnosed and undertreated >>

Author Antonio
Vallejo-Vaz, of Imperial College, London, talks to medical journalist Dr Jane Stock about the FHSC and these findings.

FH related reports and videos from EAS 2019 Maastricht

Maastricht welcomed over 2,000 delegates from 70 countries to the 87th Congress of the European Atherosclerosis Society (EAS), a reflection of the global presence of the Society.

The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) is an important example of the Society’s global position in atherosclerosis research. Currently, 68 countries have entered 59,600 FH cases in this Registry. The EAS FH Studies Registry has recently announced a collaboration with the patient representative network, FH Europe, to ensure that there is now one voice for FH in Europe.

Read more in the reports and listen to experts discussing recent findings and activities aimed at establishing best practices in management and treatment of FH worldwide.

Reports and video interview with FHSC representatives

Photo from the FH Studies Collaboration Steering Committee meeting in Maastricht, May 29, 2019 in conjunction with the EAS 2019 Congress

Read the report "Failure to diagnose familial hypercholesterolaemia results in worse outcome" from one of the Late breaking abstract sessions at the Congress and listen to the video interview with Professor Ray, Scientific leader of the FHSC, discussing the importance of early diagnosis of familial hypercholesterolemia.

Recent news from the EAS FHSC Registry has highlighted the extent of unmet needs in FH research and care, emphasising the importance of this initiative. Listen to Dr. Antonio J. Vallejo-Vaz from the FHSC Co-ordinating Centre in Imperial College London, UK discussing the survey of FH status in more than 60 countries participating in the FHSC Registry and some of the FH Lead Investigators discuss the status of FH care and new initiatives in FH that have been a direct consequence of participation in the FHSC Registry.

To the report "Failure to diagnose familial hypercholesterolaemia
results in wore outcome" >>

To the video interviews with FHSC representatives about the Registry >>

One voice in Europe on FH

Photo from the partnership representatives meeting in Maastricht, May 26, 2019 in conjunction with the EAS 2019 Congress

Earlier this year, the European Atherosclerosis Society initiative FH Studies Collaboration and the patients organisation network "FH Europe" announce partnership.

Through this collaboration FH Europe and the FHSC will speak withone voice on FH, and by linking FH patient groups with expert clinicians from all over the world, we will share globally established best practices that will mean more persons with FH are identified early and, once they are identified, a smoother pathway for the patient to referral and potentially life-saving treatment in the clinic.

Read about the partnership and the intentions with the collaboration >>

Improving FH care: the role of patient advocacy - A report from the EAS FH Studies Collaboration

Preceding the opening of the EAS Maastricht Congress, patient organisation representatives from FH Europe and FHSC researchers met to discuss opportunities and challenges in setting up a patient organisation. Opening this session, Professor Kausik Ray, lead of the EAS FHSC, emphasised the key role of patient advocacy in lobbying policy makers about FH.

While recognising that issues related to setting up an FH patient organisation may differ between countries, representatives from FH Europe highlighted key approaches that have proved successful.

Listen to some of the patient organisation representatives describing their situation and work in their respective country/area

 To the report on "Improving FH care"
and the video interviews >

EAS Publications and Educational activites on FH

To FH related Consensus Papers :: EAS ACADEMY - Certificate in FH

Membership Software Powered by YourMembership  ::  Legal